TY - JOUR AU - Xu, Hanxiao AU - Niu, Mengke AU - Yuan, Xun AU - Wu, Kongming AU - Liu, Aiguo PY - 2020 DA - 2020/12/10 TI - CD44 as a tumor biomarker and therapeutic target JO - Experimental Hematology & Oncology SP - 36 VL - 9 IS - 1 AB - CD44, a complex transmembrane glycoprotein, exists in multiple molecular forms, including the standard isoform CD44s and CD44 variant isoforms. CD44 participates in multiple physiological processes, and aberrant expression and dysregulation of CD44 contribute to tumor initiation and progression. CD44 represents a common biomarker of cancer stem cells, and promotes epithelial-mesenchymal transition. CD44 is involved in the regulation of diverse vital signaling pathways that modulate cancer proliferation, invasion, metastasis and therapy-resistance, and it is also modulated by a variety of molecules in cancer cells. In addition, CD44 can serve as an adverse prognostic marker among cancer population. The pleiotropic roles of CD44 in carcinoma potentially offering new molecular target for therapeutic intervention. Preclinical and clinical trials for evaluating the pharmacokinetics, efficacy and drug-related toxicity of CD44 monoclonal antibody have been carried out among tumors with CD44 expression. In this review, we focus on current data relevant to CD44, and outline CD44 structure, the regulation of CD44, functional properties of CD44 in carcinogenesis and cancer progression as well as the potential CD44-targeting therapy for cancer management. SN - 2162-3619 UR - https://doi.org/10.1186/s40164-020-00192-0 DO - 10.1186/s40164-020-00192-0 ID - Xu2020 ER -